Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. issues news on its virtual primary care and pharmacy services business, including telemedicine, laboratory access, pharmacy fulfillment, and specialized treatment programs across primary care, men's and women's health, weight management, and hormone therapy. Updates often cover its digital care platform, affiliated medical group, pharmacy infrastructure, patient care center, and branded GLP-1 access within weight management.
For LFMDP, company news also includes dividends on LifeMD's 8.875% Series A Cumulative Perpetual Preferred Stock. Other recurring items include financial results, investor conference participation, credit facilities, and executive leadership changes.
LifeMD (Nasdaq: LFMD) announced it is now offering Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) through its weight management program via an integration with LillyDirect. The FDA approved Foundayo on April 1, 2026.
Foundayo is available to eligible patients with a starting self-pay price of $149/month, commercial patients may pay as little as $25/month with a Lilly savings card, and Medicare coverage is anticipated July 2026. LifeMD says the addition expands its branded GLP-1 offerings and supports virtual, clinically guided weight-management services.
LifeMD (Nasdaq: LFMD) launched Novo Nordisk's industry-first Wegovy® (semaglutide) telehealth subscription program on March 31, 2026, expanding its commercial collaboration with Novo Nordisk. Eligible patients can receive structured pricing with up to $1,200 annual savings for injectable Wegovy and $600 for oral therapy.
The program offers end-to-end virtual care across all 50 states, ongoing clinical oversight, nationwide diagnostic testing, and simplified billing, and is available at LifeMD's weight management site.
LifeMD (Nasdaq: LFMD) declared a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share.
The dividend is payable April 15, 2026, to holders of record at the close of business on April 3, 2026.
LifeMD (Nasdaq: LFMD) appointed Atul Kavthekar as Chief Financial Officer, effective March 16, 2026, and announced additional leadership changes to support growth. Marc Benathen will remain through March 31, 2026, to assist transition. LifeMD disclosed an employment inducement of 675,000 restricted stock units for Mr. Kavthekar, split between service- and performance-based vesting.
LifeMD also named Chris Pisano Chief Marketing Officer and promoted Jessica Friedeman to Chief Business Officer; Friedeman joined LifeMD in January 2023.
LifeMD (Nasdaq: LFMD) reported full year 2025 revenue of $194.1 million (up 25%) and adjusted EBITDA of $15.3 million (up 309%). Q4 revenue was $46.9 million (+4%) with adjusted EBITDA of $4.8 million (+348%).
The company exited 2025 with $36.8 million cash, no debt, ~323,000 active subscribers, a benefits infrastructure to cover ~220 million Americans by Q2, and a post‑year‑end launch of oral Wegovy with >80% initiation among new weight management patients.
LifeMD (Nasdaq: LFMD) announced management will participate in two virtual investor conferences in March 2026.
Management will attend the Mizuho Securities Healthcare Technology Conference on March 5 with virtual one-on-one meetings, and the KeyBanc Capital Markets Healthcare Forum March 17-18 with a fireside chat and a panel on March 18.
LifeMD (Nasdaq: LFMD) will report fourth quarter and full-year 2025 financial results after market close on March 9, 2026 and will host a conference call and webcast at 4:30 p.m. Eastern the same day.
Dial-in numbers, conference ID LIFEMD, and a live/archived webcast link will be available for investors.
LifeMD (Nasdaq: LFMD) closed a new senior secured revolving credit facility with Citizens Bank providing up to $50 million of total availability, consisting of $30 million committed availability plus an accordion option of up to $20 million. The facility matures on January 2, 2029. As of closing, no amount was drawn and the company stated it expects existing cash and cash flow to fund organic growth. Interest is priced on a leverage-linked grid at either Term SOFR +150–225 bps or Alternate Base Rate +50–125 bps, with unused-commitment fees of 0.225%–0.30% and no upfront fee.
LifeMD (NASDAQ: LFMD) expanded its collaboration with Novo Nordisk to offer Wegovy pill (oral semaglutide) through LifeMD’s telehealth and integrated NovoCare Pharmacy services. The U.S. FDA approved the Wegovy pill on Dec 22, 2025 as the first oral GLP-1 for chronic weight management and certain cardiovascular risk reduction. A 64-week Phase 3 trial showed 16.6% mean weight loss versus 2.7% for placebo. Eligible patients can access Wegovy pills via LifeMD starting at $149/month, with staged price increases effective Apr 15, 2026. LifeMD offers virtual visits, nationwide testing, clinical oversight, and home delivery across all 50 states.
LifeMD (Nasdaq: LFMD) announced a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share. The dividend is payable on January 15, 2026 to holders of record at the close of business on January 5, 2026. This declaration establishes the payment amount and the key record and payment dates for preferred shareholders.